scholarly journals A Systematic Review of Long Noncoding RNAs in Hepatocellular Carcinoma: Molecular Mechanism and Clinical Implications

2018 ◽  
Vol 2018 ◽  
pp. 1-13 ◽  
Author(s):  
Xiaoge Hu ◽  
Jiahong Jiang ◽  
Qiuran Xu ◽  
Chao Ni ◽  
Liu Yang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Systematic Review ◽  
Mortality Rate ◽  
Molecular Mechanisms ◽  
Potential Role ◽  
Noncoding Rnas ◽  
Long Noncoding Rnas ◽  
Clinical Implications ◽  
Current Review ◽  
Complex Process

Hepatocellular carcinoma (HCC) has the second highest mortality rate worldwide among all cancers. Previous studies have revealed the significant involvement of long noncoding RNAs (lncRNAs) in numerous human cancers including HCC. Both oncogenic and tumor repressive lncRNAs have been identified and implicated in the complex process of hepatocarcinogenesis. They can be further explored as prospective diagnostic, prognostic, and therapeutic markers for HCC. An in-depth understanding of lncRNAs’ mechanism in HCC is therefore required to fully explore their potential role. In the current review, we will concentrate on the underlying function, molecular mechanisms, and potential clinical implications of lncRNA in HCC.

scholarly journals Long Noncoding RNAs as a Key Player in Hepatocellular Carcinoma

2017 ◽  
Vol 9 ◽  
pp. 1179299X1773730 ◽  
Author(s):  
Mrigaya Mehra ◽  
Ranjit Chauhan
Keyword(s):  
Hepatocellular Carcinoma ◽  
Molecular Mechanisms ◽  
Structural Integrity ◽  
Gene Expression Regulation ◽  
Noncoding Rnas ◽  
Clinical Applications ◽  
Long Noncoding Rnas ◽  
Protein Coding ◽  
Cellular Processes ◽  
The World

Hepatocellular carcinoma (HCC) is a major malignancy in the liver and has emerged as one of the main cancers in the world with a high mortality rate. However, the molecular mechanisms of HCC are still poorly understood. Long noncoding RNAs (lncRNAs) have recently come to the forefront as functional non–protein-coding RNAs that are involved in a variety of cellular processes ranging from maintaining the structural integrity of chromosomes to gene expression regulation in a spatiotemporal manner. Many recent studies have reported the involvement of lncRNAs in HCC which has led to a better understanding of the underlying molecular mechanisms operating in HCC. Long noncoding RNAs have been shown to regulate development and progression of HCC, and thus, lncRNAs have both diagnostic and therapeutic potentials. In this review, we present an overview of the lncRNAs involved in different stages of HCC and their potential in clinical applications which have been studied so far.

scholarly journals Molecular mechanisms of circular RNAs, transforming growth factor‐ β , and long noncoding RNAs in hepatocellular carcinoma

2019 ◽  
Vol 8 (15) ◽  
pp. 6684-6699 ◽  
Author(s):  
Wenkang Shang ◽  
Gabriel Komla Adzika ◽  
Yujie Li ◽  
Qike Huang ◽  
Ningding Ding ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Growth Factor ◽  
Molecular Mechanisms ◽  
Transforming Growth Factor ◽  
Noncoding Rnas ◽  
Transforming Growth Factor Β ◽  
Long Noncoding Rnas ◽  
Circular Rnas

scholarly journals Lnc-ATG9B-4 aggravates progress of hepatocellular carcinoma through cell proliferation and migration by upregulating CDK5

2020 ◽  
pp. 153537022096319
Author(s):  
Ming Li ◽  
Le Wei ◽  
Pin-Yue Liu ◽  
Xue-Mei Zhang ◽  
Fang Liu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Tumor Thrombus ◽  
Molecular Mechanisms ◽  
Noncoding Rnas ◽  
Carcinoma Cells ◽  
Long Noncoding Rnas ◽  
Hepatocellular Carcinoma Cells ◽  
Tumor Capsule ◽  
Tumor Tissues ◽  
Degree Of Differentiation

Long noncoding RNAs play an important role in the occurrence, invasion, as well as metastasis of various human cancers, including hepatocellular carcinoma. Long noncoding RNAs can affect the biological functions of hepatocellular carcinoma cells by regulating various genes; however, only a small fraction of molecular mechanisms of long noncoding RNAs have been elucidated. In the present study, lnc AC010973.1 (lnc-ATG9B-4) was first identified by microarray analysis from 8 patients with hepatocellular carcinoma and confirmed by quantitative PCR in 176 patients with hepatocellular carcinoma. We demonstrated that lnc-ATG9B-4 was tightly relative to the tumorous size, TNM stages, portal vein tumor thrombus (PVTT), the tumor capsule, metastasis, degree of differentiation, and poor prognosis of hepatocellular carcinoma according to long-term follow-up data. In hepatocellular carcinoma cells, overexpression of lnc-ATG9B-4 promoted proliferation, invasion, as well as migration, while inhibiting lnc-ATG9B-4 by siRNA significantly attenuated the proliferation, invasion, as well as migration. Interestingly, lnc-ATG9B-4 increased the expression of cyclin-dependent kinase 5 (CDK5), which was closely related to the development and chemotherapy sensitivity of hepatocellular carcinoma. In summary, our results revealed that lnc-ATG9B-4 suggests an unfavorable prognosis of hepatocellular carcinoma and facilitates the proliferation, invasion, as well as migration of hepatocellular carcinoma cells by upregulating CDK5. This research suggests that lnc-ATG9B-4 may be a new biomarker for predicting the prognosis of hepatocellular carcinoma; meanwhile, targeting lnc-ATG9B-4 might serve as a potential strategy for the treatment hepatocellular carcinoma. Impact statement In this study, we explored the expression profile of lncRNA in HCC tumor tissues and paracancerous tissues using microarray assays. Furthermore, a new lncRNA (lnc-ATG9B-4) was identified, which was about 3.5 times more expressed in tumor tissues than in paracancerous tissues. Through clinicopathological analysis, lnc-ATG9B-4 was determined to be related to the tumorous size, TNM stages, portal vein tumor thrombus (PVTT), the tumor capsule, metastasis, and the degree of differentiation. Lnc-ATG9B-4 promoted the proliferation, invasion, as well as migration of the HCC cells by upregulating the expression of CDK5. Here, we further exploited the molecular mechanisms of lnc-ATG9B-4 to screen new drug intervention targets for recurrence and metastasis of HCC.

The 9p21 Locus and its Potential Role in Atherosclerosis Susceptibility; Molecular Mechanisms and Clinical Implications

2016 ◽  
Vol 22 (37) ◽  
pp. 5730-5737 ◽  
Author(s):  
Amir Tajbakhsh ◽  
Mohammad Khorrami ◽  
Seyed Hassanian ◽  
Malihe Aghasizade ◽  
Alireza Pasdar ◽  
...  
Keyword(s):  
Molecular Mechanisms ◽  
Potential Role ◽  
Clinical Implications ◽  
9P21 Locus

scholarly journals Recent Advances in Nanotechnology with Nano-Phytochemicals: Molecular Mechanisms and Clinical Implications in Cancer Progression

2021 ◽  
Vol 22 (7) ◽  
pp. 3571
Author(s):  
Bonglee Kim ◽  
Ji-Eon Park ◽  
Eunji Im ◽  
Yongmin Cho ◽  
Jinjoo Lee ◽  
...  
Keyword(s):  
Cancer Progression ◽  
Animal Studies ◽  
Molecular Mechanisms ◽  
Future Research ◽  
Clinical Implications ◽  
Research Perspectives ◽  
Current Review ◽  
Gold Silver ◽  
Significant Efficacy ◽  
Rapid Clearance

Biocompatible nanoparticles (NPs) containing polymers, lipids (liposomes and micelles), dendrimers, ferritin, carbon nanotubes, quantum dots, ceramic, magnetic materials, and gold/silver have contributed to imaging diagnosis and targeted cancer therapy. However, only some NP drugs, including Doxil® (liposome-encapsulated doxorubicin), Abraxane® (albumin-bound paclitaxel), and Oncaspar® (PEG-Asparaginase), have emerged on the pharmaceutical market to date. By contrast, several phytochemicals that were found to be effective in cultured cancer cells and animal studies have not shown significant efficacy in humans due to poor bioavailability and absorption, rapid clearance, resistance, and toxicity. Research to overcome these drawbacks by using phytochemical NPs remains in the early stages of clinical translation. Thus, in the current review, we discuss the progress in nanotechnology, research milestones, the molecular mechanisms of phytochemicals encapsulated in NPs, and clinical implications. Several challenges that must be overcome and future research perspectives are also described.

Four long noncoding RNAs as potential prognostic biomarkers for hepatocellular carcinoma

2018 ◽  
Vol 234 (6) ◽  
pp. 8709-8716 ◽  
Author(s):  
Jianchu Wang ◽  
Jian Pu ◽  
Tianwei Yao ◽  
Xiaojie Lu ◽  
Yibin Deng
Keyword(s):  
Hepatocellular Carcinoma ◽  
Noncoding Rnas ◽  
Long Noncoding Rnas ◽  
Prognostic Biomarkers
Sign in / Sign up

Export Citation Format

Share Document